← Back to patent-cliff list
CAS 4105-38-8
Triacetyl uridine
Codes: Molnupiravir-038
Application context (from source-drug indications)
COVID-19Molnupiravir呼吸道合胞体病毒感染MolnupiravirInfluenza virus infectionMolnupiravirRenal impairmentMolnupiravirHepatic function declineMolnupiravir
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Molnupiravir | Tier B — Position early | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
2,4(1H,3H)-Pyrimidinedione→D-Ribofuranose 1,2,3,5-tetraacetate→Triacetyl uridine→4-Chloro-1-(2,3,5-tri-O-acetyl-beta-D-ribofuranosyl)pyrimidin-2(1H)-one→2',3',5'-Tri-O-acetyl-N-hydroxycytidine→N4-Hydroxycytidine
Intermediates available on this site
Side-by-side comparison of all listed offers on this CAS; price bands are list-price ranges, final price subject to RFQ confirmation.
| Supplier | Product | Price band | MOQ | Lead time | Qualifications | Action |
|---|---|---|---|---|---|---|
| Unibest Taizhou GMP-like Site | ((3aR,4R,6R,6aR)-6-(4-(hydroxyamino)-2-oxopyrimidin-1(2H)-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl isobutyrate Pharmaceutical Intermediates | On request | On request | On request | — |
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.